Exposure of AML cells to CD82 mAb inhibited the survival of AML cells in vitro (data not shown), excluding the possibility that the treatment with CD82 mAb stimulated the proliferation of CD34+ leukemia cells in vivo. This evidence concerns the gene CD34 and acute myeloid leukemia.